Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report
Karina A. Pasquevich, Lorena M. Coria, Ana Ceballos, Bianca Mazzitelli, Juan Manuel Rodriguez, Agostina Demaría, Celeste Pueblas Castro, Laura Bruno, Lucas Saposnik, Melina Salvatori, Augusto Varese, Soledad González, Veronica V. González Martínez, Jorge Geffner, Diego Álvarez, Laboratorio Pablo Cassará R&D and CMC group for ARVAC-CG, Ethel Feleder, Karina Halabe, Pablo E. Perez Lera, Federico Montes de Oca, Julio C. Vega, Mónica Lombardo, Gustavo A. Yerino, Juan Fló, Juliana Cassataro
medRxiv 2023.01.10.22284009; doi: https://doi.org/10.1101/2023.01.10.22284009